Clinical trials: Non-Segmental Vitiligo
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks.
- Trial name
- NCT03715829
- Testing
- PF-06651600, PF06700841, narrow-band UVB phototherapy
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 366 people
- Sponsor
- Pfizer
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo
Topical Methotrexate with Fractional CO2 Laser in Treatment of Non Segmental Vitiligo
This prospective, within subject clinical trial aims to evaluate the efficacy of combining fractional CO2 laser with topical methotrexate versus topical methotrexate alone in treating non-segmental vitiligo.
- Trial name
- NCT06877455
- Testing
- Fractional CO2 laser assisted PDT
- Volunteers
- 50 people
- Sponsor
- Assiut University
Vitiligo
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
- Trial name
- NCT04811131
- Testing
- ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment
- Where
- 5 sites in United States
- Volunteers
- 114 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Vitiligo
Topical Delgocitinib for Facial Vitiligo
This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face.
- Trial name
- DelVito (NCT07820098)
- Testing
- Delgocitinib cream
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Lone Skov
Vitiligo
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- Viti-Up (NCT06118411)
- Testing
- Upadacitinib, NB-UVB (narrow-band ultraviolet B) Phototherapy
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 614 people
- Sponsor
- AbbVie
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Adult Subjects With Non-Segmental Vitiligo
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo
To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.
- Trial name
- NCT07712523
- Testing
- QY201 Tablets(5mg）, QY201 Tablets（10mg）, QY201 Tablets（20mg）
- Where
- China
- Volunteers
- 200 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
The purpose of this study is to determine whether afamelanotide and narrow band UVB are effective in the treatment of non-segmental vitiligo (NSV).
- Trial name
- NSV (NCT01382589)
- Testing
- Afamelanotide, NB-UVB
- Volunteers
- 15 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Non Segmental Vitiligo
Transplantation of Autologous Non-Cultured Extracted Hair Follicle Outer Root Sheath Cell Suspension and Mini Punch Graft for Stable Non-Segmental Vitiligo Lesions
Vitiligo is an acquired pigmentation disorder due to loss of melanocytes characterized by depigmentation macules or patches. One type of this disease is nonsegmental vitiligo (NSV).
- Trial name
- NCT06619184
- Testing
- NCEHFORSCS transplantation, MPG procedure
- Where
- Indonesia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Universitas Padjadjaran
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Vitiligo
A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
- Trial name
- Nb-UVB (NCT07174024)
- Testing
- Narrow Band UVB Treatment, blue light emitting diode
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Non-segmental Vitiligo
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it.
- Trial name
- NCT06113328
- Testing
- MK-6194
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Merck Sharp & Dohme LLC
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Non-Segmental Vitiligo (NSV)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Vitiligo
Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo
This study is to evaluate the effectiveness and tolerability of autologous punch minigraft, transverse needling technique or combination of both followed by narrow band ultraviolet B phototherapy (311 nm) in the treatment of…
- Trial name
- NCT03872804
- Testing
- Autologous punch mini grafts:, Transverse needling, Punch minigrafts followed by transverse needling
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Vitiligo
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
Vitiligo is a common acquired, depigmenting skin disease that affect the patient's psychological state and quality of life.
- Trial name
- NCT05008887
- Testing
- Methotrexate, 5-fluorouracil, Fractional CO2 laser
- Volunteers
- 50 people
- Sponsor
- Assiut University
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie